1174 related articles for article (PubMed ID: 17906201)
1. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
3. Redefining the refined retroperitoneal lymph node dissection in testis cancer: a SWOT analysis of nonrandomized data.
Garnick MB
J Clin Oncol; 2007 Oct; 25(28):4337-8. PubMed ID: 17906195
[No Abstract] [Full Text] [Related]
4. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
5. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
[TBL] [Abstract][Full Text] [Related]
6. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
[TBL] [Abstract][Full Text] [Related]
7. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
Eggener SE; Carver BS; Sharp DS; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2007 Mar; 177(3):937-42; discussion 942-3. PubMed ID: 17296380
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
9. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection.
Ehrlich Y; Yossepowitch O; Kedar D; Baniel J
BJU Int; 2006 Jun; 97(6):1221-4. PubMed ID: 16686715
[TBL] [Abstract][Full Text] [Related]
10. Retroperitoneal lymph node dissection after chemotherapy.
Winter C; Raman JD; Sheinfeld J; Albers P
BJU Int; 2009 Nov; 104(9 Pt B):1404-12. PubMed ID: 19840021
[TBL] [Abstract][Full Text] [Related]
11. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
12. Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings.
Brown JA; Bihrle R; Foster RS
Urology; 2008 May; 71(5):911-4. PubMed ID: 18342916
[TBL] [Abstract][Full Text] [Related]
13. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
Heidenreich A; Thüer D; Polyakov S
Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
[TBL] [Abstract][Full Text] [Related]
14. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract][Full Text] [Related]
15. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
Svatek RS; Spiess PE; Sundi D; Tu SM; Tannir NM; Brown GA; Kamat AM; Wood CG; Pisters LL
Cancer; 2009 Mar; 115(6):1310-7. PubMed ID: 19156903
[TBL] [Abstract][Full Text] [Related]
17. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
18. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?
Steiner H; Peschel R; Bartsch G
BJU Int; 2008 Aug; 102(3):310-4. PubMed ID: 18325053
[TBL] [Abstract][Full Text] [Related]
19. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
[TBL] [Abstract][Full Text] [Related]
20. [Retroperitoneal lymph node dissection for patients with advanced testicular tumor].
Takasaki N; Ueda H; Isurugi K
Hinyokika Kiyo; 1994 Oct; 40(10):957-61. PubMed ID: 7992714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
